,In this editorial, our team analyzes the implications of Colombia’s recent regulatory transition for biological products. The article explores the modernization of the regulatory framework and its alignment with international standards, while highlighting the opportunities and challenges this shift represents for the pharmaceutical industry.
Click here to read the full article to understand how this change may impact registration procedures, traceability, and compliance in the region.